Function and prognostic value of basement membrane -related genes in lung adenocarcinoma

Abstract

Background: Lung adenocarcinoma (LUAD) has become a common cause of cancer-related death. Many studies have shown that the basement membrane (BM) is associated with the development of cancer. However, BM-related gene expression and its relationship to LUAD prognosis remains unclear.Methods: BM-related genes from previous studies were used. Clinical and mRNA expression information were obtained from TCGA database. Cox, minimum absolute contraction, and selection operator regression were applied to analyze the selected genes affecting LUAD prognosis. A prognostic-risk model was then established. Furthermore, this study applied Kaplan-Meier analysis to assess the outcomes of high- and low-risk groups, then explored their differences in drug sensitivity. The DSigDB database was used to screen for therapeutic small-molecule drugs.Results: Fourteen prognostic models based on BM-related genes were successfully constructed and validated in patients with LUAD. We also found that independence was a prognostic factor in all 14 BM-based models. Functional analysis showed that the enrichment of BM-related genes mainly originated from signaling pathways related to cancer. The BM-based model also suggested that immune cell infiltration is associated with checkpoints. The low-risk patients may benefit from cyclopamine and docetaxel treatments.Conclusion: This study identified a reliable biomarker to predict survival in patients with LUAD and offered new insights into the function of BM-related genes in LUAD.

Identification and Validation of Basement Membrane Related LncRNA Signatures as a Novel Prognostic Model for Hepatocellular Carcinoma

“…BM invasion is pivotal for tumor metastasis (Chang and Chaudhuri 2019), spotlighting the significance of BM-related genes (BMGs) in cancer research. Studies have shown that models based on BMGs effectively predict outcomes and immunotherapy impacts in solid tumors like lung adenocarcinoma (Zhang et al 2023), pancreatic cancer (Zhou et al 2024), and prostate cancer (Xie et al 2024). In 2023, Sun W et al (Sun et al 2023) developed a prognostic model for HCC using BMGs, aiding clinicians in prognosis assessment and guiding immunotherapy and medication choices.…”